FDA: BioDelivery Sciences Should Improve “Safe Use” REMS Provisions For Oral Fentanyl Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Onsolis “complete response” letter is “as close to approval as one can get without having it,” BDSI CEO says.
You may also be interested in...
Onsolis' REMS Is Not Template For Long-Acting Opiates - FDA
FDA signaled it is moving ahead with action on short-acting opioid products - and their Risk Evaluation and Mitigation Strategies - on a case-by-case basis with the approval of BioDelivery Sciences International's buccal fentanyl product Onsolis for cancer breakthrough pain
Onsolis' REMS Is Not Template For Long-Acting Opiates - FDA
FDA signaled it is moving ahead with action on short-acting opioid products - and their Risk Evaluation and Mitigation Strategies - on a case-by-case basis with the approval of BioDelivery Sciences International's buccal fentanyl product Onsolis for cancer breakthrough pain
FDA Warns Approval Of BioDelivery's Fentanyl Product Onsolis Is One Of A Kind
Onsolis' REMS is no template for long-acting opiates under the agency's classwide requirement, FDA says.